The role of cirrhosis in the etiology of hepatocellular carcinoma

Journal of Gastrointestinal Cancer

Volumn 45, Issue 1, 2014, Pages 12-21

  Kew, Michael C ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cirrhosis; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Metabolic syndrome

Indexed keywords

ANTIVIRUS AGENT; CELL DNA; PROTEIN P53; PROTEIN P73; REACTIVE OXYGEN METABOLITE; TELOMERASE; UVOMORULIN;

AFRICA SOUTH OF THE SAHARA; AGE DISTRIBUTION; ALCOHOL ABUSE; ANTIVIRAL THERAPY; CHINESE; DISEASE ASSOCIATION; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; JAPANESE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER REGENERATION; LOW RISK POPULATION; MALIGNANT TRANSFORMATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RACE DIFFERENCE; REGULATOR GENE; REVIEW; RISK FACTOR; STEATOSIS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RISK FACTORS;

EID: 84896316986     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-013-9556-9     Document Type: Review

References (138)

1. Parkin DM, Bray F, Ferlay J. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:74-108.
2. Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Sem Liv Dis. 1984;4:136-46.
3. Kew MC, Dos Santos HA, Sherlock S. The diagnosis of primary cancer of the liver. Br Med J. 1971;4:408-11.
4. Leevy CM, Gellene R, Ning M. Primary liver cancer in cirrhosis of the alcoholic. Ann NYAcad Sci. 1964;114:1026-40.
5. Johnson PJ, Krasner N, Portmann BC, et al. Hepatocellular carcinoma in Great Britain: influence of age, sex, HBsAg status and etiology of underlying cirrhosis. Gut. 1978;19:1022-6. (Pubitemid 9037604)
6. Sun B, Karin M. Obesity, inflammation and liver cancer. J Hepatol. 2012;56:704-13.
7. Fung J, Lai CL, Yen MF. Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect. 2009;15:964-70.
8. Sung JL, Wang TH, Yu JY. Clinical study of primary carcinoma of the liver in Taiwan. Amer J Dig Dis. 1967;12:1036-49.
9. Alpert E, HuttMSR, Davidson CS. Primary hepatoma in Uganda. A prospective clinical and epidemiological study of 46 patients. Amer J Med. 1969;46:794-802.
10. Lai CL, Lam K, Wong KP, et al. Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer. 1981;47:2746-55. (Pubitemid 11113743)
11. Kew MC, Geddes EW. Hepatocellular carcinoma in rural southern African Blacks. Medicine (Balt). 1982;61:98-108. (Pubitemid 12158546)
12. Melia WM, Wilkinson ML, Portmann BC, et al. Hepatocellular carcinoma in the non-cirrhotic liver : a comparison with that complicating cirrhosis. Quart J Med. 1984;53:390-4.
13. Ihde DC, Sherlock P, Winawer SJ, et al. Clinical manifestations of hepatocellular carcinoma. Amer J Med. 1974;56:83-9.
14. Omata M, AshcavaiM, Liew CT, et al. Hepatocellular carcinoma in the U.S.A: etiologic considerations. Gastroenterology. 1979;76:279-87.
15. Ferenci P, Dragosics B, Marosi L, et al. Relative incidence of primary liver cancer in cirrhosis in Austria. Etiological considerations. Liver. 1984;4:7-14. (Pubitemid 14129901)
16. Gibson JB,Wu PC, Ho JCI, et al. HBsAg, hepatocellular carcinoma and cirrhosis in Hong Kong. A necropsy study. Br J Cancer. 1980;42:370-7. (Pubitemid 10024627)
17. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26:177-82.
18. Prates MD. Cancer and cirrhosis of the liver in the Portuguese East African. J Natl Cancer Inst. 1965;35:729-57.
19. Kew MC, Geddes EW, MacNab GM, et al. Hepatitis B antigen and cirrhosis in Bantu patients with primary liver cancer. Cancer. 1974;34:538-41.
20. Kew MC. Hepatocellular carcinoma: with and without cirrhosis. Gastroenterology. 1989;97:136-9.
21. Kew MC. The role of cirrhosis in hepatocarcinogenesis. In: Bannasch P, Keppler D, Weber G, editors. Liver cell carcinoma. Dordrecht: Kluwer; 1989. p. 37-46.
22. Okuda K, Nakashima T, Sakamoto K, et al. Hepatocellular carcinoma arising in non-cirrhotic and highly cirrhotic livers. Cancer. 1982;49:450-5.
23. Steiner PE. Cancer of the liver and cirrhosis in trans-Saharan Africa and the U.S.A. Cancer. 1960;13:1085-145.
24. Tong M, Sun SC, Schaeffer BT, et al. Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med. 1971;75:687-91.
25. Kew MC. Hepatitis C, virus and hepatocellular carcinoma. FEMS Microbiol Rev. 1994;14:211-9.
26. Kew MC, Asare GA. Dietary iron overload in the African and hepatocellular carcinoma. Liv Internat. 2007;27:735-41. (Pubitemid 47062039)
27. Paterson AC, Isaacson C. Hepatocellular carcinoma in an urban Black community: a changing pattern. Virchow Arch A Pathol Anat Histol. 1982;395:273-8.
28. Beasely RP, Hwang LY. Hepatocellular carcinoma and the hepatitis B virus. Sem Liv Dis. 1984;4:113-21.
29. Botha JF, RitchieMJJ, Dusheiko GM, et al. Hepatitis B virus carrier State in Black children in Ovamboland: role of peri-natal and horizontal infection. Lancet. 1984;2:1209-12.
30. Caldwell S, Park SH. The epidemiology of hepatocellular carcinoma from the perspectives of public health problem to tumor biology. J Gastroenterol. 2009;44(Suppl XIX):96-101.
31. MacDonald RA. Primary carcinoma of the liver. A clinicopathological study of 108 cases. Arch Intern Med. 1957;99:266-77.
32. Purtilo DJ, Gottlieb LS. Cirrhosis and hepatoma occurring at Boston City Hospital. Cancer. 1973;32:458-62.
33. Higginson J. The geographical pathology of primary liver cancer. Cancer Res. 1963;23:1624-33.
34. Lee FI. Cirrhosis and hepatoma in alcoholics. Gut. 1967;7:77-85.
35. Dong CH, Yoon YH, Chen CM, et al. Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006. J Stud Alcohol Drugs. 2011;72:892-902.
36. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006;7: 149-56. (Pubitemid 43159501)
37. Schafer DF, Sorrell M. Hepatocellular carcinoma. Lancet. 1999;353:1253-7. (Pubitemid 29168472)
38. Shikata T. Primary liver carcinoma and liver cirrhosis. In: Okuda K, Peters RL, editors. Hepatocellular carcinoma. New York: Wiley; 1976. p. 53-71.
39. MacDonald RA. Primary carcinoma of the liver: a clinicopathological study of 108 cases. Arch InternMed. 1957;99:266-79.
40. Okuda K, Nakashima T, Sakamoto K, et al. Hepatocellular carcinoma arising in non-cirrhotic and highly-cirrhotic livers: a comparative study of histopathology and frequency of hepatitis B markers. Cancer. 1982;49:450-5. (Pubitemid 12213441)
41. Becker BJP, Chatkidakis CB. Primary carcinoma of the liver in Johannesburg. Acta Unio Int Conctra Cancrum. 1961;17:650-3.
42. Purtilo DT, Gottlieb LS. Cirrhosis and hepatoma occurring at Boston City Hospital (1917-1968). Cancer. 1973;32:458-62.
43. Scheuer PJ. Pathogenesis and morbid anatomy of human primary liver cancer. IARC Sci Pub. 1971;1:13-20.
44. Thomson TG. Primary carcinoma of the liver in the three ethnic groups in Cape Town. Acta Unio in Contra Cancrum. 1961;17:632-8.
45. Leevy CM, Gellene R, Ning M. Primary liver cancer in cirrhosis of the liver. Ann NYAcad Sci USA. 1964;114:1026-40.
46. Zaman ZN, Melia WM, Johnson RD, et al. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet. 1985;1:1357-9.
47. Zhang DY, Friedman CL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012;56:769-75.
48. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-46. (Pubitemid 35253462)
49. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006;25:3834-947.
50. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C virus-related advanced liver disease. Gastroenterology. 2009;136:138-48.
51. McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene. 2011;30:1969-83.
52. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448-558.
53. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010;29:2309-24.
54. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol. 2006;14:6756-65. (Pubitemid 44811395)
55. Obata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. 2003;97:303603043.
56. Moriya K, Yotsuynagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997;78:1527-31. (Pubitemid 27343089)
57. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as an indicator of oxidative stress inpatients with hepatitis C virus infection. J Hepatology. 2000;13:159-63.
58. Mahmood S, Kawanaka M, Kamei A, et al. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid Redox Signal. 2004;6:19-24. (Pubitemid 38063973)
59. Gong G, Waris G, Tanveer R, et al. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB. Proc Natl Acad Sci U S A. 2001;98:9599-604. (Pubitemid 32769349)
60. Tsai WL, Chung RT. Viral hepatocarcinogeneis. Oncogenesis. 2010;29:2309-24.
61. Tardif KD,Mori KL, Siddiqui A. Hepatitis C subgenomic replicons reduce endoplasmic reticulum stress activating an intracellular signalling pathway. J Virol. 2002;76:7453-9. (Pubitemid 34760967)
62. Agemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol. 2013;35:111-20.
63. Wang T, Weiman SA. Cause and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J Gastroenterol. 2006;21:S34-7. (Pubitemid 44266547)
64. Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc. 2009;120:361-8.
65. Waris G, Turkson J, Hassanein T, et al. Hepatitis C virus constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol. 2005;79:1569-80. (Pubitemid 40459104)
66. Takeya R, Sumimoto H. Regulation of novel superoxide-producing NAD(P)H. Antoxid Redox Signal. 2006;8:1523-32.
67. Machida K, Cheng KT, Lai CK, et al. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT-3 activation. J Virol. 2006;80:7199-207. (Pubitemid 44025216)
68. Ray RB, Steele R,Meyer K, et al. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem. 1997;272:10983-6. (Pubitemid 27184081)
69. Yamanaka Kodama T, Doi T, et al. Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression. Biochem Biophys Res Commun. 2002;294:528-34. (Pubitemid 34694040)
70. Arora P, KimEO, Jung K, et al. Hepatitis C virus core protein downregulates E-cadherin expression by activation of DNA methyltransferases 1 and 3b. Cancer Lett. 2008;261:244-52.
71. Taniguchi H, Kato N, Otsuka M, et al. Hepatitis C protein upregulates transforming growth factor-β 1 transcription. J Med Virol. 2004;72:52-9. (Pubitemid 37484743)
72. Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with chronic hepatitis C virus infection perturbs hepatic transforming growth factor β signalling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007;46:48-57. (Pubitemid 47171920)
73. Hayashi J, Aoki H, Kajino K, et al. Hepatitis C virus core proteín activated the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor alpha. Hepatology. 2000;32:958-61.
74. Fukutomi T, Zou Y, Kawai S, et al. Hepatitis C virus core proteín stimulates hepatocyte growth: correlation with up-regulation of Wnt-1 expression. Hepatology. 2005;41:1096-105. (Pubitemid 40593917)
75. Moriya K, Fujie H, Shintani Y, et al. Hepatitis C virus core protein induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065-8.
76. Kwun HJ, Jang KL. Dual effects of hepatitis C virus core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene. J Viral Hepat. 2003;10:249-55. (Pubitemid 36801910)
77. Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002;195:35-41. (Pubitemid 34074494)
78. Zhao LJ, Wang L, Ren H, et al. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ ERK signalling pathway via cellular receptors. Exp Cell Res. 2005;305:23-32. (Pubitemid 40380650)
79. Deng L, Nagano-Fujii M, Tanaka M, et al. NS3 protein of hepatitis C virus associates with the tumor suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol. 2006;87:1703-13. (Pubitemid 43827226)
80. Hassan M, Ghozhan H, Abel-Kader O. Activation of c-Jun NH2- terminal kinase signalling pathway is essential for the stimulation of hepatitis C virus non-structural protein 3- mediated cell growth. Virology. 2005;333:324-36. (Pubitemid 40250116)
81. Hassan M, Selimovic D, Ghozlan H, et al. Induction of high molecular weight tumor necrosis factor-α by hepatitis C virus non-structural protein 3 in liver cells is AP-1 and NFκB-dependent activation. Cell Signal. 2007;19:1469-82.
82. Majumder M, Ghosh AK, Steele R, et al. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression expression in a p53-dependent manner. JVirol. 2001;75:1401-7. (Pubitemid 32094698)
83. Lan KH, Sheu ML, Hwang HJ, et al. NS5A interacts with p53 and inhibits 53-mediated apoptosis. Oncogene. 2002;21:4801-11.
84. Qadri I, IwahashiM, Simon F, et al. Hepatitis C virus NS5A protein binds TBP and p53, inhibiting their binding and p53 interactions with TBP and ERCC3. Biochem Biophys Acta. 2002;21:193-204.
85. Chung YL, Sheu ML, Yen SH. Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int J Cancer. 2003;107:65-73.
86. Ghosh AK, Malunder M, Steele R, et al. Hepatitis C virus NS5A protein protects against TNF-α -mediated apoptotic cell death. Virus Res. 2000;67:173-8. (Pubitemid 30365170)
87. Bonte D, Francois C, Castelain S, et al. Positive effect of the hepatitis C virus non-structural 5A protein on viral multiplication. Arch Virol. 2004;149:1353-71. (Pubitemid 38927638)
88. Choi SH, Hwang SB. Modulation of the transforming growth factor-β signal transduction pathway by hepatitis C virus nonstructural 5A protein. J Biol Chem. 2006;281:7468-78. (Pubitemid 43847519)
89. Wu SC, Chang SC,Wu HY, et al. NS5A protein down-regulates the expression of spindler gene Aspm through PKR-38 signalling pathway. J Biol Chem. 2008;283:29396-404.
90. Gieling RG, Burt AD,Mann DA. Fibrosis and cirrhosis - molecular mechanisms. Clin Liv Dis. 2008;12:915-57.
91. Das K, Coudhury A. Hepatic fibrosis: can we treat it clinically? Trop Gastroenterol. 2008;29:76-83.
92. KannM. Structural and molecular virology. In: Lai CL, Locarnini S, editors. Hepatitis B virus. London: International Medical Press; 2002. p. 9-22.
93. World Health Organization. Hepatitis B vaccines. WHO Website 2003.
94. World Health Organization. World Health Organization fact sheet 2004 (revised October 2000) WHO Website, 2000
95. EASL International Consensus Conference on Hepatitis B. Consensus statement. J Hepatol. 2003;39:S3-S25.
96. Trichopoulos D, Tabor E, Gerety RJ, et al. Hepatitis B and primary hepatocellular carcinoma in a European population. Lancet. 1978;2:1217-9. (Pubitemid 9071902)
97. Orito E, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus genotypes in patients with chronic hepatitis B virus infection in Japan. Hepatology. 2001;34:590-4. (Pubitemid 32786652)
98. Livingston SE, Simonetti JP, MacMahon BJ. Hepatitis B virus genotypes in Alaskan native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007;195:5-11. (Pubitemid 44958221)
99. Kew MC, Kramvis A, Yu MC, et al. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub- Saharan Africans. J Med Virol. 2005;75:513-21. (Pubitemid 40293518)
100. Brechot C, Piourcel C, Louise A, et al. Presence of integrated hepatitis B virus DNA sequences in human hepatocellular carcinoma tissue. Nature. 1980;286:533-6.
101. Shafriz DA, Shouval D, Sherman HI, et al. Integration of hepatitis B virus DNAinto the genome of liver cells in chronic liver disease and hepatocellular carcinoma studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med. 1981;305:1067-73. (Pubitemid 12234831)
102. Matsubara KM, Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med. 1990;7:243-60. (Pubitemid 20283937)
103. Takada S, Gotoh Y, Hayashi S, et al. Structural rearrangement of integrated hepatitis B virus DNA as well as cellular flanking DNA is present in chronically infected hepatic tissues. J Virol. 1990;64:822-8. (Pubitemid 20032699)
104. Wang J, Zindt F, Chenvisse X, et al. Modification of cyclin A expression by HBV DNA integration in a HCC. Oncogene. 1992;7:1652-6.
105. Schluter V,MeyerM, Hofschneider PH, et al. Integrated hepatitis B virus x and 3′ preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene. 1994;9:3335-44.
106. Horikawa J, Barrett JC. Cis -activation of the human telomerase gene by the hepatitis B virus genome. J Natl Cancer Inst. 2001;93:1171-3. (Pubitemid 32780970)
107. Dandri M, Burda MR, Burkle A, et al. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADPribosyl)ation. Hepatology. 2002;35:217-23. (Pubitemid 34032563)
108. Murakami Y, Saigo G, Takashima H, et al. Large scale analysis of hepatitis B virus DNA integration in HBV related hepatocellular carcinoma. Gut. 2005;54:1162-8. (Pubitemid 41025914)
109. Livingston SE, Simonetti JP,MacMahon BJ, et al. Hepatitis B virus integration, fragile sites and hepatocarcinogenesis. Cancer Lett. 2007;252:158-70.
110. Schluter V, MeyerM, Hofschneider PH, et al. Integrated hepatitis B virus x and truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene. 1994;9:3335-44.
111. Guerrero RB, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol. 2005;42:760-6.
112. Arbuthnot P, Kew MC. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol. 2001;82:77-100.3.
113. Paterlini P, Poussin K, KewMC, et al. Selective accumulation of the x transcript of hepatitis B virus in patients negative for hepatitis B virus surface antigen with hepatocellular carcinoma. Hepatology. 1995;21:313-21.
114. Rogler CE, Chisari FV. Cellular and molecular mechanisms of hepatocarcinogenesis. Sem Liver Dis. 1992;12:265-78.
115. Kew MC. Hepatitis B, virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:144-52.
116. Wang HC, HuangW, LaiMD, et al. Hepatitis B virus preS mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci. 2006;97:683-8. (Pubitemid 43983778)
117. LiuH, Luan F, JuY, et al. In vitro transfection of the hepatitis B virus preS2 gene into the human hepatocarcinoma cell line Hep G2 induces upregulation of human telomerase reverse transcriptase. Biochem Biophys Res Commun. 2007;355:379-84.
118. Baptista M, Kramvis A, Kew MC. High prevalence of 1762(T)1764(A) mutations in the basic core promoter of hepatitis B virus isolated from Black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology. 1999;29:946-53. (Pubitemid 29109614)
119. Kao JH, Chen PJ, Lai MY, et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology. 2003;124:327-34.
120. Brechot C. Pathogenesis of hepatitis B virus related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127(5 Suppl 1):556-61.
121. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents adults, 1999-2002. JAMA. 2004;291:2847-50. (Pubitemid 38747805)
122. Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36:150-5. (Pubitemid 34700772)
123. Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127:S97-S103. (Pubitemid 39423375)
124. Guzman G, Brunt EM, Petrovic LM, et al. Does alcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med. 2008;132:1761-6.
125. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111-21.
126. Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am. 2010;39:567-8.
127. Dominguez-Melagon H, Gratan-Graham S. Hepatocellular carcinoma: an update. Ultrastruct Pathol. 2001;25:497-516.
128. Hu W, Feng Z, Eveleigh J, et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenol preferentially forms DNA adducts of codon 249 of human p53 gene, a uniquemutational hotspot in hepatocellular carcinoma. Carcinogenesis. 2002;23:1781-9. (Pubitemid 35355927)
129. Hsu JC, Peng JY, Lai PL, et al. Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinoma. Cancer. 1994;73:42-7.
130. Diehl AM, Li ZP, Lin HZ, et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut. 2005;54:303-6. (Pubitemid 40139250)
131. Elchuri S, Oberley TD, Qi W, et al. CuZnSOD deficiency leads to p e r s i s t e n t and widespread oxidat ive damage and hepatocarcinogenesis later in life. Oncogene. 2005;24:367-80. (Pubitemid 40188585)
132. Xu Z, Chen I, Leung I, et al. Liver-specific inactivation of the Nrf1 in adult mice leads to non alcoholic steatosis and hepatic neoplasia. Proc Natl Acad Sci U S A. 2005;102:4120-5. (Pubitemid 40388565)
133. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of non-alcoholic fatty liver disease. Hepatology. 2005;42:665-74. (Pubitemid 41233660)
134. Friedman SL. Hepatic stellate cells: protean, multifunctional and enigmatic cells of the liver. Physiol Rev. 2008;88:125-72.
135. Van Zijl F,MairM, Csiszar A, et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene. 2009;12:4022-33.
136. Taura K, De Minicis S, Seki E, et al. Hepatic stem cells secrete angiopoietin1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008;135:1729-38.
137. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:889-900.
138. Russo MW. Antiviral therapy for hepatitis C is associated with improved outcomes in patients with advanced fibrosis. Exp Rev Gastroenterol Hepatol. 2010;4:535-9.